Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Net (2016 - 2025)

Lineage Cell Therapeutics' Receivables - Net history spans 15 years, with the latest figure at $891000.0 for Q4 2025.

  • For Q4 2025, Receivables - Net rose 39.66% year-over-year to $891000.0; the TTM value through Dec 2025 reached $891000.0, up 39.66%, while the annual FY2025 figure was $891000.0, 39.66% up from the prior year.
  • Receivables - Net reached $891000.0 in Q4 2025 per LCTX's latest filing, up from $127000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $50.6 million in Q4 2021 to a low of $77000.0 in Q1 2024.
  • Average Receivables - Net over 5 years is $3.0 million, with a median of $365500.0 recorded in 2021.
  • The largest YoY upside for Receivables - Net was 1265900.0% in 2021 against a maximum downside of 99.55% in 2021.
  • A 5-year view of Receivables - Net shows it stood at $50.6 million in 2021, then tumbled by 99.41% to $297000.0 in 2022, then surged by 135.69% to $700000.0 in 2023, then decreased by 8.86% to $638000.0 in 2024, then surged by 39.66% to $891000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Receivables - Net are $891000.0 (Q4 2025), $127000.0 (Q3 2025), and $256000.0 (Q2 2025).